🐋 UNH $6M Aggressive Call Buying — Whales Loading Up Above Ask Before Q1 Earnings!

📅 April 13, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just dropped $6 MILLION on UNH call options in two trades, with BOTH fills coming in ABOVE the ask price — that's the options market equivalent of sprinting to the checkout counter and paying more than the sticker price. The two trades target $350 and $400 strikes expiring December 2026, with UnitedHealth Group currently sitting at $307.53 — implying belief the stock recovers 14% to 30% from here in the next 8 months. With Q1 earnings just 8 days away and a favorable Medicare Advantage rate decision already in the books, this is a sizeable, urgent bet on UNH's recovery story.

---

📊 Company Overview

UnitedHealth Group (NYSE: UNH) is the largest U.S. private health insurer and one of the most vertically integrated healthcare companies in the world:

• Market Cap: $276.2B
• Sector: Healthcare / Insurance
• Exchange: NYSE
• Current Price: $307.53
• 52-Week Range: $234.67 - $606.36 (yes, the stock has been cut nearly in half from highs)
• Members: 51M+ globally, including 94% of Medicare eligibles through its Medicare Advantage plans
• Primary Business: Health insurance (UnitedHealthcare), care delivery (Optum Health, 90,000+ physicians), pharmacy (Optum Rx, $154.7B revenue), data/analytics (Optum Insight)
• Recent Financials: 2025 revenue $448B (+12% YoY); adjusted EPS $16.35; medical care ratio 89.1%
• Current Context: Stock down ~49% from its 52-week high amid Medicare Advantage cost pressures, DOJ antitrust litigation, and its first revenue decline guidance in 30 years — but has bounced sharply (+11% on April 7) on favorable Medicare Advantage rate news for 2027

---

💰 The Option Flow Breakdown

📊 The Tape (April 13, 2026)

🤓 What This Actually Means

Both trades arrived at the exact same timestamp (12:00:01) — this is a coordinated, simultaneous two-leg buy. Here's the breakdown:

Leg 1 — The Primary Bet:

• 💰 $3.9M in the $350 calls (2,000 contracts at $19.73)
• 📍 Strike distance: $350 is 13.8% above current $307.53 — needs a solid recovery to pay off
• 📊 Volume 2,500 vs. OI 791 — 3.2x the existing open interest, fresh new position

Leg 2 — The Lottery Ticket:

• 💰 $2.1M in the $400 calls (2,400 contracts at $8.74)
• 📍 Strike distance: $400 is 30% above current price — deep out-of-the-money, high conviction
• 📊 Volume 3,000 vs. OI 3,100 — nearly 1-to-1 with existing OI, meaningful new interest

The Above-Ask Signal: Both fills came in ABOVE the ask price — the buyer was so eager to get these filled that they paid a premium over the listed price. In options, buying above ask is unusual and signals urgency and conviction. This isn't a patient limit-order trader — they wanted these contracts and were willing to pay extra to ensure execution. That kind of behavior typically comes from someone acting on a strong thesis ahead of a binary catalyst.

Combined structure: This two-leg simultaneous buy creates a position that profits from an aggressive UNH recovery by December 2026. The $350 calls provide the primary payoff; the $400 calls are the high-leverage "if things really go right" kicker.

Time horizon: December 18, 2026 — 248 days away. This captures Q1 earnings (April 21), Q2 earnings (late July), Q3 earnings (late October), two Medicare Advantage rate cycles, and the DOJ antitrust discovery phase resolution.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

UNH has had a brutal stretch — the stock peaked at $606.36 and has been slashed nearly in half. The January 2026 guidance disappointment (first revenue decline in 30 years) sent shares down ~20% in a single session, per Fortune. However, on April 7, the stock surged 11% on the CMS Medicare Advantage rate decision — its best single day in over a year. The buyers today appear to believe that April 7 was an inflection point, not a dead-cat bounce.

Key observations:

• 📉 Deep value territory: Trading at ~17x forward earnings vs. historical 20-25x range — the stock is genuinely cheap IF the thesis normalizes
• 📈 April 7 catalyst: 5%+ Medicare Advantage rate increase for 2027 was the single most important policy catalyst UNH needed
• 🔵 Floor testing: Stock has been testing the $290-$310 range as potential base-building territory
• ⚠️ Overhead is heavy: Enormous resistance exists from traders who bought higher; a move back toward $350+ requires real fundamental improvement

Gamma-Based Support & Resistance Analysis

Current Price: ~$311.66

🔵 Support Levels (Put Gamma Below Price):

• $310 — Immediate support at 20.3B total gamma — the strongest support level. Almost at current price, so this is actively being defended.
• $300 — Secondary floor at 21.0B total gamma — also robust, makes $300 psychologically and technically significant
• $290 — Extended support at 8.1B total gamma
• $280 — Deep support at 9.4B total gamma
• $250 — Structural floor at 4.3B total gamma

🟠 Resistance Levels (Call Gamma Above Price):

• $315 — Immediate resistance at 5.1B total gamma (just above current price)
• $320 — Notable resistance at 15.5B total gamma — the first major ceiling to clear
• $330 — Resistance at 8.8B total gamma
• $340 — Resistance at 5.1B total gamma
• $350 — Meaningful resistance at 8.6B total gamma — exactly where Leg 1 of this trade is struck!

What this means for traders: UNH has strong two-sided support at $300-$310 (combined ~41B gamma), which should limit near-term downside. The path to $350 requires clearing resistance at $315, $320, $330, $340, and $350 in sequence. Each of those gamma resistance walls creates natural selling pressure. The call buyer is essentially betting UNH works through all of them over the next 8 months.

Net GEX Bias: Bullish (99.5B call gamma vs. 55.3B put gamma) — dealer positioning heavily tilts bullish, meaning market makers will generally support price action on dips.

Implied Move Analysis

Options market-implied price ranges:

• 📅 This Week (April 17 — 4 days): ±$6.74 (±2.16%) → Range: $304.60 - $318.08
• 📅 May OPEX (May 15): Upper $323.54 / Lower $299.14
• 📅 June Triple Witch (June 19): Upper $331.82 / Lower $290.86
• 📅 July OPEX (July 17): Upper $335.97 / Lower $286.71
• 📅 August OPEX (August 21): Upper $342.18 / Lower $280.50
• 📅 September Triple Witch (Sept 18): Upper $348.39 / Lower $274.29
• 📅 December Triple Witch (Dec 18 — THIS TRADE): Upper $364.96 / Lower $257.72
• 📅 1-Year LEAPS (March 2027): ±$70.00 (±22.5%) → Range: $241.34 - $381.34

Translation for regular folks: By December 18, 2026 — when these calls expire — the options market implies a range of $257.72 to $364.96. The $350 strike call sits just below the upper boundary of what the market considers a plausible scenario. The $400 call sits well above the implied upper boundary, meaning it prices in a scenario the market currently considers unlikely but possible.

For the $350 calls to be profitable, UNH needs to trade above $369.73 ($350 + $19.73 premium paid) by December 18 — that's a 20% move from today. For the $400 calls: above $408.74 — a 33% move from today. These aren't conservative bets. The buyer needs a significant recovery, not just a bounce.

---

🎪 Catalysts

🔥 Immediate Catalysts (Next 30 Days — CRITICAL)

Q1 2026 Earnings — April 21, 2026 (8 DAYS AWAY!) 📊

This is the single most important near-term catalyst. Q1 2026 is Stephen Hemsley's first "clean" quarter as returning CEO — no large cyberattack charges, no restructuring noise. Market consensus per IndexBox:

• Revenue: ~$109.7B (down from the $113.2B Q4 level, reflecting market exits)
• Adjusted EPS: $6.62 - $6.69 (down 8% YoY from $7.20 — decline is expected and mostly priced in)
• Key metrics to watch: Medical Care Ratio (MCR) trajectory, membership count (how much attrition from plan exits), Optum Health recovery path, 2026 full-year guidance reaffirmation

The $6M call buyer placed their bet 8 days before this print — they believe the Q1 report will be better than feared or at minimum will confirm the bottom. Per CNBC's Q4 2025 coverage, Q4 missed revenue estimates but beat EPS — a Q1 beat on both metrics could be the needed trigger.

🚀 Near-Term Catalysts (Q2-Q3 2026)

Medicare Advantage 2027 Rate Decision — Already Done ✅

The biggest policy win is already in the books: CMS finalized a 5%+ total payment increase for 2027 Medicare Advantage plans on April 7, 2026, far exceeding the flat increase initially proposed. UNH serves 94% of Medicare eligibles — this rate hike directly improves plan economics for 2027. Bank of America raised its price target to $337 on the news.

Analyst Upgrade Momentum 📈

Raymond James upgraded UNH on April 1, 2026 with a $330 price target. MarketBeat's consensus tracker shows 24 analysts with Buy ratings and an average target of $377.83 — 23% upside from current levels. That $377 consensus target is directionally aligned with where the $350 call buyer needs the stock to go.

Optum Health Stabilization

After a brutal 2025 — Optum Health revenue fell to $102B (from a $7.8B operating profit swing to a $(278)M operating loss), per Seeking Alpha — management expects 2026 stabilization through continued value-based care investment. Any evidence of Optum Health returning to positive operating income would be a significant positive surprise.

AI Cost Reduction Program 🤖

UNH has targeted ~$1B in AI-enabled operating cost reductions in 2026. Evidence of margin improvement at Q1 earnings would validate this initiative and support the multiple re-rating thesis.

Q2 2026 Earnings (Late July 2026)

This earnings will be critical — it will reveal whether MCR is genuinely stabilizing after UNH exited 600,000+ unprofitable Medicare Advantage members. If MCR trends down from the 89.1% 2025 level, the stock could make a meaningful recovery move.

⚠️ Risk Catalyst — DOJ Antitrust Litigation (Mid-2026)

The DOJ omnibus antitrust lawsuit filed October 2025 targets UNH's vertical integration — patient steering, Optum Insight data practices. A February 2026 supplemental filing expanded scope to Optum Insight's "informational monopoly." Discovery enters in mid-2026 — potentially surfacing damaging internal documents and creating headline risk in the heart of the call option's life.

The December expiration on these calls means they live through the entire DOJ discovery phase. The call buyer is comfortable holding through that uncertainty — but retail traders should understand it as a real risk within the trade window.

---

🎲 Price Targets & Probabilities

🐂 Bull Case — $350 to $375 (25-35% probability by December 18)

• Requires: Q1 earnings beat + MCR improvement + Optum Health stabilization + DOJ settlement (not forced breakup)
• Path: Clear gamma resistance at $315 → $320 → $330 → $340 → $350
• $350 gamma resistance (8.6B) is actually not the heaviest level — meaningful but clearable
• Aligns with the $350 call breakeven ($369.73) and analyst average target ($377.83)
• The December implied upper range is $364.96 — the market says this range is plausible

⚖️ Base Case — $310 to $340 (45-55% probability)

• Gradual recovery as fundamentals stabilize but DOJ uncertainty caps multiple expansion
• Both sets of calls expire with minimal value — the $350s might have some worth, $400s expire worthless
• Consistent with the implied move mid-range
• Supported by $310 gamma floor (20.3B) and $300 secondary floor (21.0B)

🐻 Bear Case — $260 to $300 (15-25% probability)

• DOJ discovery reveals damaging information OR Q1 earnings disappoint badly OR medical cost trends worsen
• Would invalidate the entire call position — both legs expire worthless
• The $257.72 December implied lower boundary suggests the market sees this as possible but not likely
• $280 gamma support (9.4B) and $250 structural floor (4.3B) would be the key downside markers

Breakeven analysis:

• $350 calls: Need UNH above $369.73 at December expiration (20.2% move from today)
• $400 calls: Need UNH above $408.74 at December expiration (32.9% move from today)
• Both breakevens are ambitious — this is speculative, directional betting, not hedging

---

💡 Trading Ideas

🛡️ Conservative — "The Value Re-Rate Play"

Strategy: Buy UNH shares outright at $307.53. No options complexity.

Why this works: At ~17x forward earnings, UNH trades at the cheapest valuation in years versus its 20-25x historical range. If the Medicare Advantage rate tailwind flows through to 2027 earnings and the DOJ case settles (most likely outcome per analysts), the stock has a path to $375-$400 simply on multiple re-expansion — even with modest earnings growth.

Downside risk: You own shares, so a DOJ adverse ruling or another MCR surprise hits you dollar-for-dollar. Size appropriately.

Target: $350-$375 over 12-18 months (17% to 22% upside from here)

⚖️ Balanced — "The April Earnings Momentum Setup"

Strategy: Buy the UNH $330 call expiring June 2026 before the April 21 earnings. If Q1 beats on MCR improvement, the stock can push from $307 toward $330+ and your calls become valuable. If it disappoints, you lose your premium.

Why this works: You get defined risk into a binary catalyst with meaningful upside if the market gets the "all clear" signal it's been waiting for. June expiry gives you some time post-earnings for the move to develop.

Risk: Total loss of premium if Q1 disappoints — size this as a lottery ticket, not a core position.

🚀 Aggressive — "Mirror the Whale (Scaled Down)"

Strategy: Buy the UNH $350 December 2026 calls at or near $19.73, scaled to your account size (1-5 contracts).

Why this works: You're making the same bet as the $6M whale — that UNH recovers meaningfully into year-end on the Medicare Advantage tailwind, Q1/Q2 MCR stabilization, and eventual DOJ clarity. The December expiry gives you 8 months for the story to play out. You need UNH above $369.73 to profit.

Risk: This is an above-ask, aggressive buy on a $307 stock targeting $350+. It can absolutely go to zero if the DOJ case escalates or medical costs spiral. Only use capital you can afford to lose entirely.

The $400 kicker: If you believe in the full recovery thesis and want lottery-ticket exposure, the $400 December calls at $8.74 offer significant leverage if UNH runs to $420+. Small sizing only.

---

⚠️ Risk Factors

DOJ Antitrust Lawsuit — The Elephant in the Room: The DOJ's omnibus suit targeting UNH's vertical integration is the single most significant risk. Discovery in mid-2026 could surface damaging materials. Even if settlement is the most likely outcome (per analysts), the process creates headline risk throughout the call options' life. A forced divestiture of Optum Insight or provider business would permanently alter UNH's earnings power and valuation multiple.

Medical Cost Trends Remain Elevated: MCR of 89.1% in 2025 reflects Medicare Advantage cost trends approaching 10% growth. The 2027 rate increase helps for NEXT year's plan economics — 2026 is still the hangover year. Any further MCR deterioration at Q1 earnings would send the stock lower and the calls underwater.

Membership Attrition: UNH is expected to lose 3M+ members in 2026 as it exits unprofitable plans. The risk: profitable members leave too. Each member lost is revenue gone, even if the per-member profitability improves.

Revenue Decline is Historic: The 2026 revenue guidance of >$439B represents UNH's first annual revenue decline in 30+ years. This signals a structural reset — not just a one-quarter blip. The market may take time to re-rate even after costs stabilize.

Political/Regulatory Scrutiny: Public backlash against managed care following the December 2024 murder of UnitedHealthcare CEO Brian Thompson, new PCP referral requirements generating member dissatisfaction, and continued Medicaid redetermination volatility all create unpredictable political risk.

Tariff-Driven Healthcare Cost Inflation: Rising costs from tariff-driven inflation could increase healthcare utilization costs, further pressuring MCR in 2026.

---

🎯 The Bottom Line

Real talk: Someone with serious resources placed a $6M, above-ask, two-leg bet on UNH's recovery story 8 days before Q1 earnings. Both fills ABOVE the ask price tell you everything — they wanted these contracts and paid up to get them. That kind of urgency typically means they have a view on the catalyst right in front of them.

The thesis is straightforward: UNH is down ~49% from its all-time high. It trades at 17x forward earnings when it historically commanded 20-25x. The April 7 Medicare Advantage rate decision (5%+ for 2027) removed the single biggest near-term policy risk. Q1 earnings on April 21 are Hemsley's first clean quarter — no cyberattack charges, no restructuring noise. If he can show MCR is stabilizing, the stock has a credible path back toward $350-$375.

If you own UNH or are bullish: This $6M call buy confirms you're not alone in that view. The December expiry gives plenty of time for the recovery thesis to play out. Q1 earnings (April 21) is your first major checkpoint — watch the MCR number closely.

If you're watching: Mark your calendar for April 21, 2026 — Q1 2026 earnings before market open. This is the single most important near-term data point. A beat, particularly on MCR trajectory, could push UNH from $307 toward $330-$340 quickly and validate the call buyer's thesis. A miss on MCR or guidance could push it back toward $280.

If you're cautious: The DOJ discovery phase starting in mid-2026 is genuinely unknowable. If you're not comfortable holding through that uncertainty, this is not the trade for you. The calls can still expire worthless even if the fundamental story improves, if DOJ headlines reset sentiment at the wrong moment.

The breakeven reality check: $369.73 for the $350 calls and $408.74 for the $400 calls are ambitious targets. These require UNH to recover 20-33% from today. Achievable? Yes. Easy? No. Size accordingly, and if you mirror this trade, only risk capital you're comfortable losing entirely.

---

Options trading involves substantial risk and is not suitable for all investors. Past performance is not indicative of future results. This analysis is for educational and informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before making investment decisions.